Mabylon further develops active substance to treat peanut allergy with Pfizer

04 September 2023 12:56

Supporting partner

Schlieren/Zurich/New York - Biotech company Mabylon has entered into an agreement with the biotech promoter Pfizer Ignite. Mabylon plans to use this to expedite the development of its innovative antibody product to treat peanut allergies.

According to a press release, Mabylon AG from Schlieren in the canton of Zurich is now working with Pfizer within the context of the Pfizer Ignite offering. Pfizer Ignite with headquarters in New York supports biotech companies with the development and commercialization of promising projects. According to Pfizer Ignite, the program offers support, strategic input, and end-to-end services including research, development, and manufacturing. Furthermore, Pfizer has the capacity and network to manufacture on a global scale.

Mabylon AG uses the therapeutic potential of naturally occuring human antibodies to treat allergies and neurodegenerative diseases. By participating in the Pfizer Ignite program, Mabylon plans to use Pfizer’s therapeutic development experience to accelerate the development of the active substance candidate MY006. The antibody product is intended to be effective in treating peanut allergies.

Mabylon’s research and development work is based on the findings of Professor Adriano Aguzzi and his colleagues at the University of Zurich and University Hospital Zurich. The company draws from this to develop antibody-based therapies to treat food allergies. Aguzzi is on the board of directors and the scientific advisory board of Mabylon.

Mabylon is a spin-off from the University of Zurich and University Hospital Zurich as well as a member of Bio-Technopark Schlieren. ce/gba 

Supporting partner

Swiss Pavilion Digital